Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae

DL Paterson, 2005, Extended-spectrum beta-lactamases: a clinical update, Clin Microbiol Rev, 18, 657, 10.1128/CMR.18.4.657-686.2005

ME Falagas, 2009, Extended-spectrum beta-lactamase-producing organisms, J Hosp Infect, 73, 345, 10.1016/j.jhin.2009.02.021

GM Rossolini, 2008, The spread of CTX-M-type extended-spectrum beta-lactamases, Clin Microbiol Infect, 14, S33, 10.1111/j.1469-0691.2007.01867.x

K Yang, 2007, Diagnosis and treatment of extended-spectrum and AmpC beta-lactamase-producing organisms, Ann Pharmacother, 41, 1427, 10.1345/aph.1K213

2004, National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992 through June 2004, issued October 2004, Am J Infect Control, 32, 470, 10.1016/j.ajic.2004.10.001

R Canton, 2008, Prevalence and spread of extended-spectrum beta-lactamase-producing Enterobacteriaceae in Europe, Clin Microbiol Infect, 14, S144, 10.1111/j.1469-0691.2007.01850.x

WH Sheng, 2013, Distribution of extended-spectrum beta-lactamases, AmpC beta-lactamases, and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal infections in the Asia-pacific region: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART), Antimicrob Agents Chemother, 57, 2981, 10.1128/AAC.00971-12

JD Pitout, 2005, Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community, J Antimicrob Chemother, 56, 52, 10.1093/jac/dki166

BE Young, 2014, A prospective observational study of the prevalence and risk factors for colonization by antibiotic resistant bacteria in patients at admission to hospital in Singapore, BMC Infect Dis, 14, 298, 10.1186/1471-2334-14-298

LY Hsu, 2007, Antimicrobial drug resistance in Singapore hospitals, Emerg Infect Dis, 13, 1944, 10.3201/eid1312.070299

M Melzer, 2007, Mortality following bacteraemic infection caused by extended spectrum beta-lactamase (ESBL) producing <italic>E</italic>. <italic>coli</italic> compared to non-ESBL producing <italic>E</italic>. <italic>coli</italic>, J Infect, 55, 254, 10.1016/j.jinf.2007.04.007

DL Paterson, 2004, Antibiotic therapy for <italic>Klebsiella pneumoniae</italic> bacteraemia: implications of production of extended-spectrum beta-lactamases, Clin Infect Dis, 39, 31, 10.1086/420816

SS Kanj, 2011, Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant <italic>Pseudomonas aeruginosa</italic>, Mayo Clin Proc, 86, 250, 10.4065/mcp.2010.0674

J Rodriguez-Bano, 2012, Beta-Lactam/beta-lactam inhibitor combinations for the treatment of bacteraemia due to extended-spectrum beta-lactamase-producing <italic>Escherichia coli</italic>: a post hoc analysis of prospective cohorts, Clin Infect Dis, 54, 167, 10.1093/cid/cir790

HM Nguyen, 2014, Determining a clinical framework for use of cefepime and beta-lactam/beta-lactamase inhibitors in the treatment of infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae, J Antimicrob Chemother, 69, 871, 10.1093/jac/dkt450

KZ Vardakas, 2012, Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum beta-lactamases: a systematic review and meta-analysis, J Antimicrob Chemother, 67, 2793, 10.1093/jac/dks301

P Nordmann, 2011, Global spread of carbapenemase-producing Enterobacteriaceae, Emerg Infect Dis, 17, 1791, 10.3201/eid1710.110655

KK Kumarasamy, 2010, Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study, Lancet Infect Dis, 10, 597, 10.1016/S1473-3099(10)70143-2

BA Rogers, 2011, Country-to-country transfer of patients and the risk of multi-resistant bacterial infection, Clin Infect Dis, 53, 49, 10.1093/cid/cir273

G Cornaglia, 2011, Metallo-beta-lactamases: a last frontier for beta-lactams?, Lancet Infect Dis, 11, 381, 10.1016/S1473-3099(11)70056-1

N Gupta, 2011, Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention, Clin Infect Dis, 53, 60, 10.1093/cid/cir202

JS Garner, 1988, CDC definitions for nosocomial infections, 1988, Am J Infect Control, 16, 128, 10.1016/0196-6553(88)90053-3

ND Friedman, 2002, Health care—associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections, Ann Intern Med, 137, 791, 10.7326/0003-4819-137-10-200211190-00007

MA Brookhart, 2006, Variable selection for propensity score models, Am J Epidemiol, 163, 1149, 10.1093/aje/kwj149

CI Kang, 2004, Bloodstream infections due to extended-spectrum beta-lactamase-producing <italic>Escherichia coli</italic> and <italic>Klebsiella pneumoniae</italic>: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy, Antimicrob Agents Chemother, 48, 4574, 10.1128/AAC.48.12.4574-4581.2004

VP Chaubey, 2010, Clinical outcome of empiric antimicrobial therapy of bacteremia due to extended-spectrum beta-lactamase producing <italic>Escherichia coli</italic> and <italic>Klebsiella pneumoniae</italic>, BMC Res Notes, 3, 116, 10.1186/1756-0500-3-116

H Ofer-Friedman, 2015, Carbapenems versus piperacillin-tazobactam for bloodstream infections of nonurinary source caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae, Infect Control Hosp Epidemiol, 36, 981, 10.1017/ice.2015.101

PD Tamma, 2015, Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum beta-lactamase bacteraemia, Clin Infect Dis, 60, 1319

L Lopez-Cerero, 2010, Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing <italic>Escherichia coli</italic> isolates, Clin Microbiol Infect, 16, 132, 10.1111/j.1469-0691.2009.02893.x

CI Kang, 2012, Piperacillin-tazobactam as an initial empirical therapy of bacteraemia caused by extended-spectrum beta-lactamase-producing <italic>Escherichia coli</italic> and <italic>Klebsiella pneumoniae</italic>, J Infect, 64, 533, 10.1016/j.jinf.2012.01.008

L Leibovici, 1998, The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection, J Intern Med, 244, 379, 10.1046/j.1365-2796.1998.00379.x

PN Harris, 2015, Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible <italic>Escherichia coli</italic> and <italic>Klebsiella spp</italic>. (the MERINO trial): study protocol for a randomised controlled trial, Trials, 16, 24, 10.1186/s13063-014-0541-9